MedPath

Pyrotinib

Generic Name
Pyrotinib
Drug Type
Small Molecule
Chemical Formula
C32H31ClN6O3
CAS Number
1269662-73-8
Unique Ingredient Identifier
CJN36EQM0H
Background

Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Clinical Trials
Related News

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Phase 2
Recruiting
Conditions
HER2 Insertion Mutation Positive Advanced NSCLC
Interventions
First Posted Date
2019-10-30
Last Posted Date
2023-12-27
Lead Sponsor
Yongchang Zhang
Target Recruit Count
30
Registration Number
NCT04144569
Locations
🇨🇳

Hunan Provincal Tumor Hospital, Changsha, Hunan, China

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer Female
Interventions
First Posted Date
2019-10-15
Last Posted Date
2023-11-21
Lead Sponsor
RenJi Hospital
Target Recruit Count
53
Registration Number
NCT04126525
Locations
🇨🇳

Renji Hospital, Shanghai, China

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Phase 2
Conditions
Metastatic Breast Cancer
HER2-positive Breast Cancer
Interventions
First Posted Date
2019-09-19
Last Posted Date
2019-09-19
Lead Sponsor
Jinming Yu
Target Recruit Count
60
Registration Number
NCT04095390
Locations
🇨🇳

Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Phase 2
Conditions
Breast Cancer Female
HER2-positive Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
Metastatic Breast Cancer
Breast Diseases
Hormone Receptor Positive Tumor
Interventions
Drug: Aromatase Inhibitors
First Posted Date
2019-09-12
Last Posted Date
2019-09-12
Lead Sponsor
Fuzhou General Hospital
Target Recruit Count
77
Registration Number
NCT04088110
Locations
🇨🇳

Fuzhou general hospital, Fuzhou, Fujian, China

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Drug: EC chemotherapy
Procedure: Surgery
First Posted Date
2019-08-26
Last Posted Date
2020-05-19
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
12
Registration Number
NCT04066790
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Phase 2
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2019-08-21
Last Posted Date
2019-08-21
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
60
Registration Number
NCT04063462
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Phase 2
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2019-07-26
Last Posted Date
2020-12-22
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
46
Registration Number
NCT04034589
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China

🇨🇳

Sun Yat-Sen University Cancer Center, Guangyuan, China

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Phase 2
Conditions
Breast Cancer
HER2-positive Breast Cancer
Interventions
First Posted Date
2019-07-25
Last Posted Date
2019-07-25
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
40
Registration Number
NCT04033172
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Phase 2
Active, not recruiting
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2019-06-28
Last Posted Date
2022-12-08
Lead Sponsor
Fudan University
Target Recruit Count
100
Registration Number
NCT04001621
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Phase 2
Conditions
Metastatic Breast Cancer
Interventions
Drug: Treatment of physician's choice
First Posted Date
2019-06-25
Last Posted Date
2019-06-25
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
256
Registration Number
NCT03997539
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy